Rilvegostomig Antibody
Rilvegostomig is a humanized bispecific IgG1 antibody that simultaneously targets the PD-1 and TIGIT immune checkpoint receptors. It is designed to enhance T-cell activation and is investigated in preclinical and clinical research, particularly for applications in oncology such as non-small cell lung cancer (NSCLC) .
Product Specifications
Target
PD-1/PD-L1
Clonality
Recombinant
Conjugation
Unconjugated
Field of Research
Cell Biology, Immunology & Inflammation
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
